Dimension Therapeutics Announces Presentations at the Upcoming American Society for Gene and Cell Therapy (ASGCT) Annual Meeting

CAMBRIDGE, Mass., April 18, 2016 (GLOBE NEWSWIRE) — Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a central organ for devastating rare diseases, today announced that oral and poster presentations will highlight the progress of two of Dimension’s lead development candidates in hemophilia B and A, DTX101 and DTX201 respectively, during the 19^th ASGCT Annual Meeting, which will take place in Washington, DC, on Friday, May 4-7, 2016. Poster presentations will also address novel scientific approaches to the pharmaceutical development and manufacturing process of the DMTX mammalian platform that is supporting Dimension’s broad product pipeline across both hemophilia and the inherited metabolic disorders.

“We are pleased that the ASGCT has chosen to highlight our highly productive collaborative partnership in translational research with the lab of Jim Wilson, MD, PhD, professor of Medicine and Pediatrics at the Perelman School of Medicine at the University of Pennsylvania,” said Annalisa Jenkins, MBBS, MRCP, Chief Executive Officer of Dimension. “The preclinical in vivo pharmacology program at Dimension continues to provide compelling evidence on our pipeline of gene therapy programs supporting our goal of multiple IND filings in the coming year. We are committed every day to innovation in the science and medicine of rare diseases associated with the liver and in the delivery of a robust, sustainable quality manufacturing platform.”
Dr. Jenkins added, “We are proud of this work and the continued momentum of our hemophilia programs and look forward to engaging with members of the gene therapy and rare disease community at ASGCT next month.”
The presentation details are as follows:
Product Candidate Presentations – Hemophilia Portfolio
Title: Optimized AAV-Mediated Human Factor VIII Gene Therapy in Hemophilia A Mice and Cynomolgus Macaques (Abstract No. 760)
Oral Session Title: Hematologic & Immunologic Diseases II
Date & Time: Saturday, May 7, 2016, 12:00 PM – 12:15 PM Eastern Time
Location: Thurgood Marshall South, Marriott Wardman Park Hotel, Washington, DC
Authors: Jenny A. Greig¹, Qiang Wang¹, Amanda L. Reicherter¹, Erin Bote¹, Deirdre McMenamin¹, Christine Draper¹, Shu-Jen Chen¹, Alexandra L. Hanlon², Tamara Goode¹, K. Reed Clark³, Samuel Wadsworth³, Lili Wang¹, James M. Wilson^{1  1}Gene Therapy Program, Department of Medicine, University of Pennsylvania, Philadelphia, PA, ²School of Nursing, University of Pennsylvania, Philadelphia, PA, ³Dimension Therapeutics, Cambridge, MA
Title: A Dose-Escalating Preclinical Study to Determine the Efficacy, MED, and Safety of a Clinical Candidate Vector in a Mouse Model of Hemophilia B (Abstract No. 227)
Poster Session Title: Hematologic & Immunologic Diseases I
Session Date & Time: Wednesday, May 4, 2016, 5:30 PM – 7:30 PM ET
Location: Exhibit Hall C & B South, Marriott Wardman Park Hotel
Authors: Lili Wang¹, John White¹, Zhenning He¹, Tamara Goode¹, Deirdre McMenamin¹, Christine Draper¹, Cassandra Brown¹, Edward A. Chroscinski¹, Lisa Kattenhorn², Gwen Wilmes², Reed Clark², Samuel Wadsworth², James M. Wilson^1 1Gene Therapy Program, Department of Medicine, University of Pennsylvania, Philadelphia, PA, ²Dimension Therapeutics, Cambridge, MA
Product Manufacturing/Processes – Poster Presentations
Title:  Particle Titer Determination and Characterization of rAAV Molecules Using Nanoparticle Tracking Analysis (Abstract No. 304)
Session Title: AAV Vectors II
Session Date & Time: Thursday, May 5, 2016, 6:00 PM – 8:00 PM ET
Location: Exhibit Hall C & B South, Marriott Wardman Park Hotel
Authors: Samantha F. Povlich, Jonathan G. Mehtala*, Gwendolyn M. Wilmes, Christopher J. Morrison, Samuel C. Wadsworth, and K. Reed Clark Dimension Therapeutics, Cambridge, MA *Malvern Instruments, Westborough, MA
Title: Purification of AAV8 using a Prototype Affinity Resin Compatible with cGMP Manufacturing (Abstract No. 460)
Session Title: Vector and Cell Engineering/Manufacturing I
Session Date & Time: Thursday, May 5, 2016, 6:00 PM – 8:00 PM ET
Location: Exhibit Hall C & B South, Marriott Wardman Park Hotel
Authors: Colleen M. Dupuis, Amy A. Medeiros, Samuel C. Wadsworth, K. Reed Clark, Christopher J. Morrison Dimension Therapeutics, Cambridge, MA
Title: Surface Adsorptive Loss of rAAV on Materials Used in cGMP Manufacturing (Abstract No. 710)
Session Title: Vector and Cell Engineering/Manufacturing II
Session Date & Time: Friday, May 6, 2016, 6:00 PM – 8:00 PM ET
Location: Exhibit Hall C & B South, Marriott Wardman Park Hotel
Authors: Monica Jiang, Colleen M. Dupuis, Amy A. Medeiros, Samuel C. Wadsworth, K. Reed Clark, Christopher J. Morrison Dimension Therapeutics, Cambridge, MA
About Dimension Therapeutics
Dimension Therapeutics, Inc. (NASDAQ:DMTX) is a leader in discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver, based on the most advanced, mammalian adeno-associated virus (AAV) gene delivery technology. Dimension is actively progressing its broad pipeline, which features programs addressing unmet needs for patients suffering from inherited metabolic diseases, including OTC deficiency and GSDIa, a collaboration with Bayer in hemophilia A, and a wholly owned clinical program in hemophilia B. The company targets diseases with readily identifiable patient populations, highly predictive preclinical models, and well-described, and often clinically validated, biomarkers. Founded in 2013, Dimension maintains headquarters in Cambridge, Massachusetts.
For more information, please visit www.dimensiontx.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the progress of Dimension’s portfolio and lead programs, the build-out and occupation of Dimension’s new facilities, and the regulatory progress of Dimension’s product candidates and programs. All such forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risks that Dimension’s product candidates, including its lead candidate, DTX101, will not successfully be developed or commercialized; and the risks described under the caption “Risk Factors” in Dimension Therapeutics’ Annual Report on Form 10-K for the year ended December 31, 2015, which is on file with the Securities and Exchange Commission, as well as other risks detailed in Dimension Therapeutics’ additional filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Dimension Therapeutics undertakes no duty to update this information unless required by law.

CONTACT:
Jean Franchi
Chief Financial Officer
Dimension Therapeutics
617-714-0709
jean.franchi@dimensiontx.com
Burns McClellan, on behalf of Dimension Therapeutics
Media: Justin Jackson
212-213-0006, ext.327
jjackson@burnsmc.com